BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 15213617)

  • 1. The role of surgery in primary gastric lymphoma: results of a controlled clinical trial.
    Avilés A; Nambo MJ; Neri N; Huerta-Guzmán J; Cuadra I; Alvarado I; Castañeda C; Fernández R; González M
    Ann Surg; 2004 Jul; 240(1):44-50. PubMed ID: 15213617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of stage one and two-E gastric large B-cell lymphoma: chemotherapy alone or surgery followed by chemotherapy?
    Sbitti Y; Ismaili N; Bensouda Y; Kadiri H; Ichou M; Errihani H
    J Hematol Oncol; 2010 Jun; 3():23. PubMed ID: 20569496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary gastric non-Hodgkin's lymphoma in Chinese patients: clinical characteristics and prognostic factors.
    Huang J; Jiang W; Xu R; Huang H; Lv Y; Xia Z; Sun X; Guan Z; Lin T; Li Z
    BMC Cancer; 2010 Jul; 10():358. PubMed ID: 20604963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
    Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
    Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
    Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
    J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified number of extranodal involved sites as a prognosticator in R-CHOP-treated patients with disseminated diffuse large B-cell lymphoma.
    Yoo C; Kim S; Sohn BS; Kim JE; Yoon DH; Huh J; Lee DH; Kim SW; Lee JS; Suh C
    Korean J Intern Med; 2010 Sep; 25(3):301-8. PubMed ID: 20830228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab as consolidation therapy did not improve outcome in patients with diffuse large B-cell lymphoma at complete response after dose-dense chemotherapy (CHOP-14).
    Avilès A; Nambo MJ; Huerta-Guzmàn J; Silva L; Neri N
    Cancer Biother Radiopharm; 2015 Apr; 30(3):107-10. PubMed ID: 25871407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of surgery and rituximab in primary gastric diffuse large B-cell lymphoma].
    Huang HW; Jiang YB; Fu TW; Xu T; Chen XC; Jin ZM; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2016 Jul; 37(7):602-6. PubMed ID: 27535862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components.
    Li X; Xia B; Guo S; Zhan Z; Zhang L; Zhao D; Wu X; Zhang Y
    Ann Hematol; 2013 Jun; 92(6):807-15. PubMed ID: 23417758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pattern of failure and optimal treatment strategy for primary gastric diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
    Kang HJ; Lee HH; Jung SE; Park KS; O JH; Jeon YW; Choi BO; Cho SG
    PLoS One; 2020; 15(9):e0238807. PubMed ID: 32960887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of therapeutic outcomes between surgical resection followed by R-CHOP and R-CHOP alone for localized primary intestinal diffuse large B-cell lymphoma.
    Lee HS; Park LC; Lee EM; Shin SH; Ye BJ; Oh SY; Song MK; Lee SM; Lee WS; Kang BW; Chang MH; Cho SG; Yahng SA; Yoon SS; Kwon JH; Kim YS
    Am J Clin Oncol; 2014 Apr; 37(2):182-7. PubMed ID: 23211226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
    Pfreundschuh M; Kuhnt E; Trümper L; Osterborg A; Trneny M; Shepherd L; Gill DS; Walewski J; Pettengell R; Jaeger U; Zinzani PL; Shpilberg O; Kvaloy S; de Nully Brown P; Stahel R; Milpied N; López-Guillermo A; Poeschel V; Grass S; Loeffler M; Murawski N;
    Lancet Oncol; 2011 Oct; 12(11):1013-22. PubMed ID: 21940214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Large bowel lymphoma: an analysis of prognostic factors and therapy in 53 patients.
    Avilés A; Neri N; Huerta-Guzmán J
    J Surg Oncol; 2002 Jun; 80(2):111-5. PubMed ID: 12173380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complications and outcomes in diffuse large B-cell lymphoma with gastric lesions treated with R-CHOP.
    Kadota T; Seo S; Fuse H; Ishii G; Itoh K; Yano T; Kaneko K; Tsukasaki K
    Cancer Med; 2019 Mar; 8(3):982-989. PubMed ID: 30730104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors in primary gastric lymphoma.
    Medina-Franco H; Germes SS; Maldonado CL
    Ann Surg Oncol; 2007 Aug; 14(8):2239-45. PubMed ID: 17546474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy alone versus surgery followed by chemotherapy for stage I/IIE large-cell lymphoma of the stomach.
    Liu HT; Hsu C; Chen CL; Chiang IP; Chen LT; Chen YC; Cheng AL
    Am J Hematol; 2000 Jul; 64(3):175-9. PubMed ID: 10861812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors and treatment efficacy in patients with primary diffuse large B-cell lymphoma of the bone: single institute experience over 11 years.
    Liu YC; Gau JP; Yu YB; Hong YC; Yen CC; Liu CY; Chao TC; Hsiao LT; Liu JH; Chiou TJ; Tzeng CH
    Intern Med; 2014; 53(2):95-101. PubMed ID: 24429447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
    Pfreundschuh M; Trümper L; Osterborg A; Pettengell R; Trneny M; Imrie K; Ma D; Gill D; Walewski J; Zinzani PL; Stahel R; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Lehtinen T; López-Guillermo A; Corrado C; Scheliga A; Milpied N; Mendila M; Rashford M; Kuhnt E; Loeffler M;
    Lancet Oncol; 2006 May; 7(5):379-91. PubMed ID: 16648042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.